KENUP-FOUNDATION
18.12.2020 15:00:16 CET | Business Wire | Press release
African reagent manufacturing for rapid testing kits and treatment for COVID-19 and other endemic diseases will be transformed by construction of a new Cape Biologix Technologies facility in Mauritius.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201218005388/en/
This will enable the company to scale up innovative plant-based manufacturing and to commercialise the successful development of plant based recombinant proteins and in particular, antibodies as a spin-off from the University of Cape Town. The manufacturing facility aims to ensure the supply of crucial reagents for the production of 100 million vaccines a month for distribution across Africa, the Caribbean and Pacific.
Initiated by kENUP Foundation, new financing from the European Investment Bank (EIB) and FIND (Foundation for Innovative New Diagnostics) for the EUR 47.5 million project was formally agreed earlier today. The EIB will provide EUR 33.3 million for the specialist manufacturing plant in Mauritius. This has been complemented by EUR 3.2 million provided by FIND that is being used to fund the rapid scale-up of the pilot phase production in Cape Town, South Africa.
“Scaling up medical innovation and specialist manufacturing is crucial to control COVID-19 and combat other diseases that can be treated, but where treatment remains a limited privilege. EIB is pleased to provide EUR 33.3 million to support Cape Biologix to expand pharmaceutical production, create jobs and increase access to affordable disease testing and treatment across Africa and around the world by increasing the affordability of key proteins. This new investment is bringing world class research from laboratories in Cape Town to improve the lives of millions of people. As part of Team Europe, the EIB is committed to working together with global partners to reduce the impact of the COVID-19 pandemic and improve public health in the years ahead.” said Ambroise Fayolle, EIB Vice President.
“Local innovation and manufacturing are critical to ensuring that quality tests can reach all who need them. We are very happy to build on our longstanding relationships in South Africa to work together on this transformative project with Cape Bio, in partnership with the EIB, translating exciting research into tangible products that will benefit everyone in the region. Building local capacity is not only needed today for COVID-19, but will also improve South Africa’s preparedness to respond to future threats.” said Dr Catharina Boehme, CEO of FIND.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201218005388/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vedanta Ltd Doubles Zinc Capacity in South Africa with US$ 600 Mn investment19.10.2026 19:19:00 CEST | Press release
Vedanta Limited doubled its annual zinc production capacity to 500,000 tonnes1in South Africa through an investment of nearly US$ 600 Mn at Gamsberg (Phase II) at Vedanta Zinc International (VZI). Gamsberg has one of the world’s most significant zinc deposits and is VZI’s flagship zinc mine. Inaugurated by South African President Cyril Ramaphosa and Vedanta Limited Director Priya Agarwal-Hebbar, this expansion marks one of the decade’s largest mining investments in South Africa. It advances Vedanta Limited’s position as the world’s largest2 zinc producer, with a vision of achieving 3 million tonnes of annual production across India and South Africa. Of this, 2 million tonnes are targeted from its subsidiary, Hindustan Zinc Limited the world’s largest integrated zinc producer, while Vedanta Zinc International business aims to contribute 1 million tonnes annually. This expansion strengthens the ZAR 21 Bn (nearly US$ 1.5 Bn) investment commitment Vedanta made at the 2018 South Africa Inve
Unlocking Digital Gold’s US$700bn Opportunity19.10.2026 18:00:00 CEST | Press release
The digital gold market, worth US$45–55bn today, could unlock up to US$700bn in latent demand, according to new research from World Gold Council and Boston Consulting Group. The report points to substantial untapped appetite among retail investors, with nearly nine in ten surveyed saying they would consider digital gold under the right conditions. The US$700bn opportunity represents the report’s estimate of total latent demand that could be released if today’s barriers to adoption were removed, rather than a near-term forecast. The report’s five-year base case sees digital gold growing by around 27% a year to US$160–170bn by 2031. That could rise to US$270–280bn over the same time if more barriers fall faster. Momentum is already building as financial markets undergo a broader digital transformation, bringing tokenised investment products increasingly into the mainstream. Tokenised gold, one segment of the digital gold market alongside vaulted digital gold, has grown fivefold in value
Roquette Brings Broad Portfolio of Excipient Solutions and Technical Expertise to AAPS PharmSci 360 202619.10.2026 16:00:00 CEST | Press release
Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will showcase its expansive portfolio of excipients, capsules, coatings, and biopharma solutions at AAPS PharmSci 360 2026. The conference and trade show will take place October 26-28 in New Orleans, Louisiana, USA. At Booth 1100 in the exhibit hall, Roquette’s Health & Pharma Solutions team will share their expertise across controlled-release technologies, hydroxypropyl beta-cyclodextrins, and sustainable formulation approaches, alongside a comprehensive portfolio of innovative solutions designed to address the evolving needs of pharmaceutical developers. “AAPS PharmSci 360 is a key opportunity to share our latest innovations, as well as highlight the breadth and depth of our scientific know-how that helps our customers solve complex formulation challenges,” said Peter Freed, Head of Technical Service & Development North America for Roquette’s Health & Pharma Solutions Business Unit. “From a
TestGorilla Survey: Recruiters are Faster with AI, but Not More Confident They’re Finding the Right Candidates19.10.2026 15:00:00 CEST | Press release
TestGorilla survey of 1,428 US talent professionalsshows nearly two in three now spend an hour or more manually checking candidates identified by AI AI made finding candidates faster for 72% of US recruiters over the last 12 months, according to TestGorilla's Recruiting in 2026 report, a survey of 1,428 US talent professionals. That speed, however, did not make them any more confident they had found the right person. In fact, of the recruiters that claim AI has made them faster, a third reported no gain in confidence at all, and 18% say their confidence in the match actually fell. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019723138/en/ Recruiters report gains in speed from AI but not in certainty - TestGorilla’s Recruiting in the AI era 2026 report Recruiters are making up the difference themselves, by hand. Of those recruiters, 67% now spend an hour or more manually checking a single candidate before they trust that
Fortanix Announces Confidential AI for Enterprise Grade Kubernetes Workloads on CNCF® Confidential Containers (CoCo)19.10.2026 15:00:00 CEST | Press release
Industry leaders including NVIDIA, Alpha Compute, AMD, Cisco, CrowdStrike, Deepgram, Dell Technologies, Eleven Labs, Fujitsu, Gnani, H2O.ai, HPE, Intel, Klique, Personal AI, Rafay, Red Hat, Resemble AI, Spectro Cloud, Supermicro, Technology Innovation Institute (TII), TELUS and VAST Data support the advancement of secure enterprise AI adoption, enabling enterprises to run frontier AI models, AI agents and AI applications on Kubernetes Fortanix® Inc., a global leader in data and AI security and pioneer of Confidential Computing, today announced support for CNCF Confidential Containers (CoCo) in Fortanix Confidential AI, enabling organizations to run AI workloads on Kubernetes inside hardware-based Trusted Execution Environments (TEEs), on confidential CPUs and GPUs. Enterprises keep the speed and agility of containers while protecting sensitive data, AI models, agents, and applications in use, so they can support their regulatory compliance efforts, scale AI across the business, and ado
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom